UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2025 or HOLOGIC, INC. (Exact name of registrant as specified in its charter) __________________________________________________________ Delaware 04-2902449 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp ...

Hologic (HOLX) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.86%. A quarter ago, it was expected that this medical device maker would post earnings of $1.02 per share when it actually produced earnings of $1.03, delivering a surprise of +0.98%.Over the last four quarters, the com ...

Hologic (HOLX) Q3 2025 Earnings Call July 30, 2025 04:30 PM ET Company ParticipantsMichael Watts - Corporate VP & IRStephen MacMillan - Chairman, CEO & PresidentEssex Mitchell - Chief Operating OfficerKarleen Oberton - CFODoug Schenkel - MD - Life Science Tools & DiagnosticsPatrick Donnelly - Managing DirectorVijay Kumar - Senior MDLu Li - Healthcare Equity Research, DirectorAnthony Petrone - MD - Equity ResearchIseult McMahon - Equity Research AssociateCasey Woodring - VP - Equity ResearchHarrison Parsons ...

Hologic (HOLX) Q3 2025 Earnings Call July 30, 2025 04:30 PM ET Speaker0Ladies and gentlemen, good afternoon, and welcome to Hologic's Third Quarter Fiscal twenty twenty five Earnings Conference Call. My name is Lisa, and I'll be your operator for today's call. Today's conference is being recorded. All lines have been placed on mute. I would now like to introduce Mike Watts, Corporate Vice President, Investor Relations to begin our call.Speaker1Thank you, Lisa. Good afternoon and thank you for joining Hologi ...

Champions of Women's Health Q3'25 Corporate Presentation Safe Harbor Statement Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; organic revenues excluding COVID-19; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net income margin; non-GAAP EPS; adjusted EBITDA; adjusted net leverage ratio and adjusted ROI ...

Exhibit 99.1 Hologic Announces Financial Results for Third Quarter of Fiscal 2025 – Revenue of $1,023.8 Million Exceeds Guidance – – Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance – – In Fourth Quarter, Company Remains on Track for Solid Revenue Growth and Faster Non-GAAP EPS Growth – MARLBOROUGH, Mass. (July 30, 2025) – Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal third quarter ended June 28, 2025. "We are pleased to ...

Key Takeaways HOLX saw Breast Health revenues fall 2.1% and 6.9% in Q1 and Q2, citing weak capital equipment demand.Hologic restructured sales teams to sharpen focus between capital and disposable product channels.HOLX's direct sales of Endomagnetics products aim to expand reach and stabilize revenue streams.Hologic (HOLX) has built a resilient Breast Health business, with its mammography products holding a leading market share. The division struggled this year, with revenues decreasing 2.1% and 6.9% in the ...

公司业绩预测 - 华尔街分析师预测Hologic季度每股收益为1.05美元，同比下降0.9% [1] - 预计季度营收为10.1亿美元，同比下降0.4% [1] - 过去30天内分析师对每股收益的共识预测保持不变 [1] 关键业务指标预测 - 妇科手术收入预计达1.7982亿美元，同比增长7.9% [4] - 分子诊断收入预计达3.1612亿美元，同比增长1.8% [4] - 血液筛查收入预计达565万美元，同比下降28.5% [5] - 乳腺成像收入预计达2.7739亿美元，同比下降10.3% [5] - 骨骼健康收入预计达2534万美元，同比增长33.4% [6] - 介入乳腺解决方案收入预计达8576万美元，同比增长13.1% [7] 业务板块表现 - 总诊断收入预计达4.3746亿美元，同比下降0.8% [5] - 细胞学和围产期诊断收入预计达1.1736亿美元，同比下降4% [6] - 总乳腺健康收入预计达3.6315亿美元，同比下降5.7% [6] - 服务及其他收入预计达2.0273亿美元，同比增长1.3% [7] - 产品收入预计达8.015亿美元，同比下降1.2% [7] 股价表现 - 过去一个月Hologic股价上涨1.5%，同期标普500指数上涨4.6% [8]

癌症诊断市场概况 - 全球癌症诊断市场因早期检测需求增加、技术进步及个性化医疗重要性提升而呈现稳定增长趋势 [1] - Hologic(HOLX)和Exact Sciences(EXAS)凭借在乳腺癌、结直肠癌筛查等领域的领先产品组合成为投资者关注焦点 [1][2] Hologic业务分析 诊断业务 - 分子诊断部门拥有Panther及Panther Fusion平台，全球装机量超3300台，已批准20+检测项目 [3] - 收购Biotheranostics技术后，新增BV/CV/TV阴道炎检测等新检测项目推动增长 [3] - 数字细胞学系统Genius推动细胞学业务强劲发展 [3] 乳腺健康业务 - 3D Genius乳腺X光机占据美国市场近80%份额 [4] - 收购Endomagnetics后增强介入性乳腺手术能力 [4] 外科业务 - MyoSure和Fluent平台主导子宫肌瘤治疗，国际增长受益于微创妇科产品市场推广 [5] - 收购Gynesonics进一步强化该部门 [5] 财务表现 - 2025财年Q2运营利润率达30%，资产负债表稳健支持并购及股票回购 [7] - 关税导致季度库存成本增加2000-2500万美元 [7] Exact Sciences业务分析 核心产品 - 旗舰产品Cologuard（结直肠癌筛查）通过再筛查计划和新增医疗提供者实现广泛增长 [8] - Oncotype DX乳腺癌检测为全球标准治疗方案，2023年获日本医保覆盖 [8] 创新管线 - 2025年3月推出Cologuard Plus，检测灵敏度95%/特异性94% [9][10] - 2025年4月推出获医保覆盖的Oncodetect（分子残留病灶检测），计划年内推出多癌早筛产品Cancerguard [10] 运营效率 - 2025年Q1调整后EBITDA同比增长61%，成本节约措施目标年化节省1800万美元 [11] - 美国本土制造避免关税影响 [11] 财务指标对比 - HOLX 2025年EPS预期4.19美元（同比+2.7%），过去90天预测趋势向下 [13][14] - EXAS 2025年EPS预期0.16美元（同比+169.6%），过去90天预测趋势向上 [14][15] - HOLX近一年股价下跌15.9%，EXAS上涨7.4% [15] - HOLX远期市销率3.47X（行业4.34X），EXAS为2.76X [16]

Key Takeaways HOLX now earns 25% of revenues internationally, with room to expand compared to peers.Hologic's International Surgical sales rose 16.2% in Q2, led by strong MyoSure and NovaSure performance.HOLX sees a global drag from Korea strikes, China headwinds and lower HIV testing in Africa.International expansion continues to play a central role in Hologic’s (HOLX) growth strategy. Currently, it generates around 25% of its total revenues from outside the United States — a lower proportion compared to o ...